Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 152

    1.

    Biological effects of low-level exposures: a perspective from U.S. EPA scientists.

    Davis JM, Farland WH.

    Environ Health Perspect. 1998 Feb;106 Suppl 1:379-81.PMID: 9539033 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Assessment of potential risk levels associated with U.S. Environmental Protection Agency reference values.

    Castorina R, Woodruff TJ.

    Environ Health Perspect. 2003 Aug;111(10):1318-25.PMID: 12896853 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Human exposure assessment and public health.

    Sexton K.

    Prog Clin Biol Res. 1991;372:455-66.PMID: 1956939 [PubMed - indexed for MEDLINE]Related articles

    4.

    Framework for metals risk assessment.

    Fairbrother A, Wenstel R, Sappington K, Wood W.

    Ecotoxicol Environ Saf. 2007 Oct;68(2):145-227.PMID: 17889701 [PubMed - indexed for MEDLINE]Related articles

    5.

    Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene.

    Clewell HJ, Andersen ME.

    Crit Rev Toxicol. 2004 Sep-Oct;34(5):385-445. Review.PMID: 15560567 [PubMed - indexed for MEDLINE]Related articles

    6.

    U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.

    Gaylor DW, Bolger PM, Schwetz BA.

    Environ Health Perspect. 1998 Feb;106 Suppl 1:391-4. Review.PMID: 9539036 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    The U.S. Environmental Protection Agency's examination of its risk assessment principles and practices: a brief perspective from the regulated community.

    Stahl RG Jr, Guiseppi-Elie A, Bingman TS.

    Integr Environ Assess Manag. 2005 Jan;1(1):86-92.PMID: 16637153 [PubMed - indexed for MEDLINE]Related articles

    9.

    Comments on article "Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene" by Clewell and Andersen.

    Caldwell JC, Evans MV, Marcus AH, Scott CS, Chiu WA, Okino MS, Preuss PW.

    Crit Rev Toxicol. 2006 Mar;36(3):291-4; discussion 295-8.PMID: 16686425 [PubMed - indexed for MEDLINE]Related articles

    10.

    A lifestage approach to assessing children's exposure.

    Cohen Hubal EA, Moya J, Selevan SG.

    Birth Defects Res B Dev Reprod Toxicol. 2008 Dec;83(6):522-9. Review.PMID: 19025791 [PubMed - indexed for MEDLINE]Related articles

    11.

    U.S. Environmental Protection Agency procedures and policies to estimate risk of injury to the male reproductive system.

    Francis EZ.

    Prog Clin Biol Res. 1989;302:3-16; discussion 17-20.PMID: 2755956 [PubMed - indexed for MEDLINE]Related articles

    12.

    Key scientific issues in the health risk assessment of trichloroethylene.

    Chiu WA, Caldwell JC, Keshava N, Scott CS.

    Environ Health Perspect. 2006 Sep;114(9):1445-9. Review.PMID: 16966103 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    State-of-the-science workshop report: issues and approaches in low-dose-response extrapolation for environmental health risk assessment.

    White RH, Cote I, Zeise L, Fox M, Dominici F, Burke TA, White PD, Hattis DB, Samet JM.

    Environ Health Perspect. 2009 Feb;117(2):283-7. Epub 2008 Sep 19.PMID: 19270800 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The U.S. EPA Science Advisory Board Evaluation (2001) of the EPA dioxin reassessment.

    Paustenbach DJ; EPA Science Advisory Board.

    Regul Toxicol Pharmacol. 2002 Oct;36(2):211-9. Review.PMID: 12460755 [PubMed - indexed for MEDLINE]Related articles

    16.

    An overview of human exposure modeling activities at the USEPA's National Exposure Research Laboratory.

    Furtaw EJ Jr.

    Toxicol Ind Health. 2001 Jun;17(5-10):302-14. Review.PMID: 12539877 [PubMed - indexed for MEDLINE]Related articles

    17.

    Assessing human health response in life cycle assessment using ED10s and DALYs: part 2--Noncancer effects.

    Pennington D, Crettaz P, Tauxe A, Rhomberg L, Brand K, Jolliet O.

    Risk Anal. 2002 Oct;22(5):947-63.PMID: 12442991 [PubMed - indexed for MEDLINE]Related articles

    18.

    VCCEP pilot: progress on evaluating children's risks and data needs.

    Williams PR, Patterson J, Briggs DW.

    Risk Anal. 2006 Jun;26(3):781-801.PMID: 16834634 [PubMed - indexed for MEDLINE]Related articles

    19.

    Low dose responses.

    Wilson R.

    Risk Anal. 2000 Jun;20(3):297-9. No abstract available. PMID: 10949407 [PubMed - indexed for MEDLINE]Related articles

    20.

    The case for integrating low dose, beneficial responses into US EPA risk assessments.

    DeSesso JM, Watson RE.

    Hum Exp Toxicol. 2006 Jan;25(1):7-10.PMID: 16459708 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data